Title: Prognostic Significance of VEGF and bFGF in Egyptian CLL Patients
Authors: Aly Fouad NT, Khodair SS, Farweez BA, Fathey HA, Elsalakawy WA
DOI: http://dx.doi.org/10.18535/jmscr/v3i9.16
Though an impressive number of prognostic factors has been identified in chronic lymphocytic leukemia (CLL), which exhibits a high variability in its clinical presentation and course, many of them have not yet been applied in routine clinical practice. Among these factors are the angiogenic factors, vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), previously reported as prognostic markers for disease progression. The objective of the present study was to assess the impact of serum VEGF and bFGF levels at diagnosis in Egyptian CLL patients and their relationship with disease prognostic parameters and patients' outcome, aiming to apply them in routine clinical practice. For this purpose, 45 newly diagnosed CLL patients and 25 healthy controls were recruited. VEGF and bFGF were found to be significantly higher in the CLL group when compared to the control group (P <0.001). Moreover, the serum concentrations of VEGF and bFGF were significantly higher in CLL patients in progressive disease state (Rai stage III and IV) and in patients with positive ZAP70 and CD38 expression. A cutoff point of >320 pg/ml for VEGF and >145 pg/ml for bFGF was able to predict poor prognosis (treatment failure) in CLL patients with prognostic accuracies of 96.7% and 89.10% respectively. In conclusion: VEGF and bFGF represent powerful prognostic markers in B-CLL, partially because of the simplicity of obtaining their samples and their assays procedure, the reliability of their assessment besides being optimal targets for potential novel therapies in conjunction with classical therapies. Keywords: VEGF, bFGF, CLL, Prognostic factors, angiogenesis. Aguirre Palma L, Gehrke I, and Kreuzer K: Angiogenic factors in chronic lymphocytic leukaemia (CLL): Where do we stand?. Crit Rev Oncol Hematol. 2015 Mar; 93(3): 225-236. Gachard N, Salviat A, Boulet C, Arnoulet C, Durrien F, Lenormand B, Lepretre S, Olschwang S, Jardin F, Lafage-Pochitaloff M, Penther D, Sainty D, Reminieras L, Fevillard J and Bene M: Multicenter study of zap-70 expression in patients with B-cell chronic lymphocytic leukemia using an optimized flow cytometry method. Haematologica 2008; 93: 215-223. Frater J, Kay N, Goolsby C, CrawfordS, Dewald G, and Peterson L: Dysregulated angiogenesis in B-chronic lymphocytic leukemia: Morphologic, immunohistochemical, and flow cytometric evidence. Diagnostic Pathology 2008, 3: 16. Smolej L, Andrys C, Maisnar V, Pour L, and Malý J: Plasma concentrations of vascular endothelial growth factor and basic fibroblast growth factor in lymphoproliferative disorders. Acta Medica (Hradec Kralove) 2005; 48(1): 57-58. Smolej L, Andrýs C, Krejsek J, Belada D, Zák P, Siroký O, and Malý J: Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) are elevated in peripheral blood plasma of patients with chronic lymphocytic leukemia and decrease after intensive fludarabine-based treatment. Vnitr Lek. 2007 Nov; 53(11): 1171-1176. Veikkola T, Karkkainen M, Claesson-Welsh L, and Alitalo K: Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 2000; 60(2): 203-212. Bairey O, Zimra Y, Shaklai M, and Rabizadeh E: Bcl-2 expression correlates positively with serum basic fibroblast growth factor (bFGF) and negatively with cellular vascular endothelial growth factor (VEGF) in patients with chronic lymphocytic leukaemia. Br J Haematol. 2001 May; 113(2): 400-406. Wrobel T, Mazur G, Dzietczenia J, Gebura K, Kuliczkowski K, and Bogunia-Kubik K: VEGF and bFGF gene polymorphisms in Polish patients with B-CLL. Med Oncol. 2013; 30: 456-460. Hallek M, Cheson B, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating M, Montserrat E, Rai K, and Kipps T: Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines. Blood 2008;111(12): 5446-5456. Gora-Tybor J, Blonski J, and Robak T: Circulating vascular endothelial Growth factor (VEGF) and its soluble receptors in patients with chronic lymphocytic leukemia. Eur cytokine Netw 2005; 16: 41-46. Smolej L, Andrys C, Peková S, Schwarz J, Belada D, and Zák P: Plasma levels of basic fibroblast growth factor and vascular endothelial growth factor and their association with IgVH mutation status in patients with B-cell chronic lymphocytic leukemia. Haematologica 2006 Oct; 91(10): 1432-1433. Kay N, Bone N, Tschumper R, Howell K, Geyer S, Dewald G, Hanson C. and Jelinek D: B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules. Leukemia 2002; 16(5): 911-919. Alavi A, Acevedo L, Min W, and Cheresh D: Chemoresistance of Endothelial Cells Induced by Basic Fibroblast Growth Factor Depends on Raf-1–Mediated Inhibition of the Proapoptotic Kinase, ASK1. Cancer Res. 2007 March 15; 67(6): 2767-2772. Wołowiec D, Dybko J, Wróbel T, Urbaniak-Kujda D, Jaźwiec B, Tomaszewska-Toporska B, Kapelko-Słowik K, Potoczek S, and Kuliczkowski K: Circulating sCD138 and some angiogenesis-involved cytokines help to anticipate the disease progression of early-stage B-cell chronic lymphocytic leukemia. Mediators Inflamm. 2006; 3: 42394. Raheem R: Immunohistochemical Expression of Vascular Endothelial Growth Factor in Chronic Lymphocytic Leukemia and its Relation to Laboratory and Clinical Findings. Medical Journal of Babylon 2012; 9(1): 27-35. Molica S, Cutrona G, Vitelli G, Mirabelli R, Molica M, Digiesi G, Ribatti D, Ferrarini M, and Vacca A: Markers of increased angiogenesis and their correlation with biological parameters identifying high-risk patients in early B-cell chronic lymphocytic leukemia. Leuk Res. 2007; 31 (11): 1575-1578. Smolej L, Andrýs C, and Vroblová V: Modern prognostic factors and angiogenesis in chronic lymphocytic leukemia: More data needed. Leukemia Research 2007; 31(12): 1763–1764. Shanafelt T, Byrd J, LaPlant B, Zent C, Call T, Secreto C, Grever M, Lin T, and Kay N: Pretreatment angiogenic cytokines predict response to chemoimmunotherapy in patients with chronic lymphocytic leukaemia. British Journal of Haematology 2009; 146: 660–664. Shanafelt T, and Kay N: The clinical and biologic importance of neovascularization and angiogenic signaling pathways in chronic lymphocytic leukemia. Seminars in Oncology 2006, 33:174–185 Maffei R, Fiorcari S, Bulgarelli J, Rizzotto L, Martinelli S, Rigolin M, Debbia G, Castelli I, Bonacorsi G, Santachiara R, Forconi F, Rossi D, Laurenti L, Palumbo A, Vallisa D, Cuneo A, Gaidano G, Luppi M, and Marasca R: Endothelium-mediated survival of leukemic cells and angiogenesis-related factors are affected by lenalidomide treatment in chronic lymphocytic leukemia. Exp Hematol. 2014 Feb;42(2):126-136.Abstract
References